OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 124
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 124
Showing 1-25 of 124 citing articles:
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 4, pp. 351-360
Closed Access | Times Cited: 41
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 4, pp. 351-360
Closed Access | Times Cited: 41
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Lei Yang, Liming Gong, Ping Wang, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2682-2682
Open Access | Times Cited: 62
Lei Yang, Liming Gong, Ping Wang, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2682-2682
Open Access | Times Cited: 62
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100423-100423
Open Access | Times Cited: 39
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100423-100423
Open Access | Times Cited: 39
Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review
Pradipta Paul, Ahmed El-Naas, Omar Hamad, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Pradipta Paul, Ahmed El-Naas, Omar Hamad, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, et al.
EBioMedicine (2023) Vol. 88, pp. 104435-104435
Open Access | Times Cited: 28
Lorenzo Azzi, Daniela Dalla Gasperina, Giovanni Veronesi, et al.
EBioMedicine (2023) Vol. 88, pp. 104435-104435
Open Access | Times Cited: 28
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review
Roxana Manuela Fericean, Cristian Oancea, Akash Reddy Reddyreddy, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 3, pp. 2150-2150
Open Access | Times Cited: 23
Roxana Manuela Fericean, Cristian Oancea, Akash Reddy Reddyreddy, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 3, pp. 2150-2150
Open Access | Times Cited: 23
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 779-811
Open Access | Times Cited: 10
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 779-811
Open Access | Times Cited: 10
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Ya Gao, Ming Liu, Zhifan Li, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 8, pp. 979-999
Open Access | Times Cited: 16
Ya Gao, Ming Liu, Zhifan Li, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 8, pp. 979-999
Open Access | Times Cited: 16
Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly
Isabella A. T. M. Ferreira, Colin Y. C. Lee, William S. Foster, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112991-112991
Open Access | Times Cited: 16
Isabella A. T. M. Ferreira, Colin Y. C. Lee, William S. Foster, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112991-112991
Open Access | Times Cited: 16
Clinical coding of long COVID in primary care 2020–2023 in a cohort of 19 million adults: an OpenSAFELY analysis
Alasdair D Henderson, Ben Butler-Cole, John Tazare, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102638-102638
Open Access | Times Cited: 6
Alasdair D Henderson, Ben Butler-Cole, John Tazare, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102638-102638
Open Access | Times Cited: 6
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Vaccine (2025) Vol. 47, pp. 126685-126685
Open Access
Júlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Vaccine (2025) Vol. 47, pp. 126685-126685
Open Access
Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population
Kazi Istiaque Sanin, Mansura Khanam, Azizur Rahman Sharaque, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 67-67
Open Access
Kazi Istiaque Sanin, Mansura Khanam, Azizur Rahman Sharaque, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 67-67
Open Access
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination
Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults
Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, et al.
Current Medical Research and Opinion (2025), pp. 1-21
Closed Access
Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, et al.
Current Medical Research and Opinion (2025), pp. 1-21
Closed Access
Vaccination Strategies: Mixing Paths Versus Matching Tracks
Achilleas Livieratos, Charalambos Gogos, Ιάσων Θωμάς, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 308-308
Open Access
Achilleas Livieratos, Charalambos Gogos, Ιάσων Θωμάς, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 308-308
Open Access
Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer
Ernest Nadal, Teresa Morán, Anna Estival, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 8, pp. 100125-100125
Closed Access
Ernest Nadal, Teresa Morán, Anna Estival, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 8, pp. 100125-100125
Closed Access
Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case–Control Study
Natthaprang Nittayasoot, Rapeepong Suphanchaimat, Panithee Thammawijaya, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2123-2123
Open Access | Times Cited: 22
Natthaprang Nittayasoot, Rapeepong Suphanchaimat, Panithee Thammawijaya, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2123-2123
Open Access | Times Cited: 22
Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project
Stefano Porru, Maria Grazia Lourdes Monaco, Gianluca Spiteri, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 3, pp. 577-588
Open Access | Times Cited: 14
Stefano Porru, Maria Grazia Lourdes Monaco, Gianluca Spiteri, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 3, pp. 577-588
Open Access | Times Cited: 14
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial
Yuzhou Gui, Xuening Li, Jingxin Li, et al.
EBioMedicine (2023) Vol. 91, pp. 104586-104586
Open Access | Times Cited: 12
Yuzhou Gui, Xuening Li, Jingxin Li, et al.
EBioMedicine (2023) Vol. 91, pp. 104586-104586
Open Access | Times Cited: 12
Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
M. Asante, Martin Ekholm Michelsen, Mithuna Mille Balakumar, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
M. Asante, Martin Ekholm Michelsen, Mithuna Mille Balakumar, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
